Adaptive Biotechnologies Corp 4

Chief Commercial Officer Susan Bobulsky sold 3,000 shares of Adaptive Biotechnologies Corp (ADPT) common stock at $25.00 per share under a Rule 10b5-1 plan.

On August 10, 2026, Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp, sold 3,000 shares of the company’s common stock at $25.00 per share in a disposition reported as a Rule 10b5-1 trading plan transaction. The sale totaled approximately $75,000 and was executed in a single transaction. Following this sale, Bobulsky beneficially owns 396,989 shares of Adaptive Biotechnologies common stock. The transaction appears to be a pre-planned diversification or liquidity event rather than a large discretionary sale, given the modest size relative to typical insider activity and the explicit reference to a previously adopted Rule 10b5-1 plan dated December 16, 2025.

Filing Facts

CIK

1478320

Ticker

ADPT

Form

4

Source Type

fda

Accession

0001820885-26-000020

Alert Tier

5